Press Release: Core shareholding in BB Biotech's portfolio reports very promising data on the R&D front

BB Biotech AG / Core shareholding in BB Biotech's portfolio reports very promising data on the R&D front . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Successful outcome of Actelion's Selexipag trial

Actelion announced the successful conclusion of its long-term trial with Selexipag, the world's first selective oral prostacyclin IP receptor agonist. If approved by regulatory authorities, it would be the first ever oral medication in the field of pulmonary arterial hypertension (PAH) targeting the prostacyclin pathways. "The outcome of the GRIPHON study puts the company back in an outstanding position for growth. Actelion now has an excellent chance of dominating the PAH market in the years ahead, not only with Opsumit but also with Selexipag," remarks Dr. Daniel Koller, Head of BB Biotech's Management Team. "In view of the positive trial outcome, we believe the shares are undervalued," he adds.

BB Biotech (ISIN CH0038389992) is one of Actelion's largest shareholders. Actelion currently accounts for 12.8% of BB Biotech's portfolio. Including the latest advances, BB Biotech has recorded unrealized gains of CHF 483 million on its investment in Actelion. As one of the early investors in this promising company with a long-term horizon, BB Biotech's investment has clearly paid off for its shareholders.

All data as of June 16, 2014, 17:30 p.m.

For further information:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland

Tanja Chicherio, Tel. +41 44 267 67 00, tch@bellevue.ch

b-public AG, Pfingstweidstrasse 6, 8005 Zurich, Switzerland

Thomas Egger, Tel. +41 79 423 22 28, teg@b-public.ch

www.bbbiotech.com

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with approx. CHF 2 billion in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

Disclaimer

This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.

Press Release (PDF): http://hugin.info/130285/R/1793536/617535.pdf

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: BB BIOTECH AG via Globenewswire

HUG#1793536

--- End of Message ---

BB BIOTECH AG

Vordergasse 3 Schaffhausen Switzerland

WKN: AONFN3;ISIN: CH0038389992;

(END) Dow Jones Newswires

   June 16, 2014 12:01 ET (16:01 GMT)- - 12 01 PM EDT 06-16-14